Literature DB >> 7774816

Assembly and function of a TCR alpha enhancer complex is dependent on LEF-1-induced DNA bending and multiple protein-protein interactions.

K Giese1, C Kingsley, J R Kirshner, R Grosschedl.   

Abstract

In this study we examine the molecular basis for the synergistic regulation of the minimal TCR alpha enhancer by multiple proteins. We find that reconstitution of TCR alpha enhancer function in nonlymphoid cells requires expression of the lymphoid-specific proteins LEF-1, Ets-1 and PEBP2 alpha (CBF alpha), and a specific arrangement of their binding sites in the enhancer. We show that Ets-1 cooperates with PEBP2 alpha to bind adjacent sites at one end of the enhancer, forming a ternary complex that is unstable by itself. Stable occupancy of the Ets-1- and PEBP2 alpha-binding sites in a DNase I protection assay was found to depend on both a specific helical phasing relationship with a nonadjacent ATF/CREB-binding site at the other end of the enhancer and on LEF-1. The HMG domain of LEF-1 was found previously to bend the DNA helix in the center of the TCR alpha enhancer. We now show that the HMG domain of the distantly related SRY protein, which also bends DNA, can partially replace LEF-1 in stimulating enhancer function in transfection assays. Taken together with the observation that Ets-1 and members of the ATF/CREB family have the potential to associate in vitro, these data suggest that LEF-1 can coordinate the assembly of a specific higher-order enhancer complex by facilitating interactions between proteins bound at nonadjacent sites.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7774816     DOI: 10.1101/gad.9.8.995

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  167 in total

1.  Regulation of cell cycle transcription factor Swi4 through auto-inhibition of DNA binding.

Authors:  K Baetz; B Andrews
Journal:  Mol Cell Biol       Date:  1999-10       Impact factor: 4.272

2.  An enhanceosome containing the Jun B/Fra-2 heterodimer and the HMG-I(Y) architectural protein controls HPV 18 transcription.

Authors:  I Bouallaga; S Massicard; M Yaniv; F Thierry
Journal:  EMBO Rep       Date:  2000-11       Impact factor: 8.807

Review 3.  Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins.

Authors:  M Bustin
Journal:  Mol Cell Biol       Date:  1999-08       Impact factor: 4.272

4.  Mechanism for specificity by HMG-1 in enhanceosome assembly.

Authors:  K B Ellwood; Y M Yen; R C Johnson; M Carey
Journal:  Mol Cell Biol       Date:  2000-06       Impact factor: 4.272

5.  Mutual activation of Ets-1 and AML1 DNA binding by direct interaction of their autoinhibitory domains.

Authors:  W Y Kim; M Sieweke; E Ogawa; H J Wee; U Englmeier; T Graf; Y Ito
Journal:  EMBO J       Date:  1999-03-15       Impact factor: 11.598

6.  Multiple layers of cooperativity regulate enhanceosome-responsive RNA polymerase II transcription complex assembly.

Authors:  K Ellwood; W Huang; R Johnson; M Carey
Journal:  Mol Cell Biol       Date:  1999-04       Impact factor: 4.272

7.  Transcriptional activation by ETS and leucine zipper-containing basic helix-loop-helix proteins.

Authors:  G Tian; B Erman; H Ishii; S S Gangopadhyay; R Sen
Journal:  Mol Cell Biol       Date:  1999-04       Impact factor: 4.272

8.  Assembly requirements of PU.1-Pip (IRF-4) activator complexes: inhibiting function in vivo using fused dimers.

Authors:  A L Brass; A Q Zhu; H Singh
Journal:  EMBO J       Date:  1999-02-15       Impact factor: 11.598

9.  A common motif within the negative regulatory regions of multiple factors inhibits their transcriptional synergy.

Authors:  J A Iñiguez-Lluhí; D Pearce
Journal:  Mol Cell Biol       Date:  2000-08       Impact factor: 4.272

10.  PIASy, a nuclear matrix-associated SUMO E3 ligase, represses LEF1 activity by sequestration into nuclear bodies.

Authors:  S Sachdev; L Bruhn; H Sieber; A Pichler; F Melchior; R Grosschedl
Journal:  Genes Dev       Date:  2001-12-01       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.